BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:soquelitinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of soquelitinib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06730126-1499@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:soquelitinib: Phase 2 readout est. (NCT06730126)
DESCRIPTION:soquelitinib\, phase 2.\nStudy: Study of the ITK Inhibitor Soqu
 elitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmun
 e Lymphoproliferative Syndrome (ALPS)-FAS Patients\nEstimated primary comp
 letion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/soquelitinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06730126
URL:https://assetmemo.bio/drug/soquelitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03952078-1499@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:soquelitinib: Phase 1 readout est. (NCT03952078)
DESCRIPTION:soquelitinib\, phase 1.\nStudy: A Dose Escalation Study Evaluat
 ing CPI-818 in Relapsed/Refractory T-Cell Lymphoma\nEstimated primary comp
 letion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/soquelitinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03952078
URL:https://assetmemo.bio/drug/soquelitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441395-1499@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:soquelitinib: Phase 2 readout est. (NCT07441395)
DESCRIPTION:soquelitinib\, phase 2\, Atopic Dermatitis.\nStudy: Study to Ev
 aluate Soquelitinib in Participants With Moderate to Severe AD\nEstimated 
 primary completion: June 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/soquelitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07441395
URL:https://assetmemo.bio/drug/soquelitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561048-1499@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:soquelitinib: Phase 3 readout est. (NCT06561048)
DESCRIPTION:soquelitinib\, phase 3\, Peripheral T-Cell Lymphoma.\nStudy: So
 quelitinib vs Standard of Care in Participants With Relapsed/Refractory Pe
 ripheral T-cell Lymphoma Not Otherwise Specified\, Follicular Helper T-cel
 l Lymphomas\, or Systemic Anaplastic Large-cell Lymphoma\nEstimated primar
 y completion: November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/soquelitinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06561048
URL:https://assetmemo.bio/drug/soquelitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07828860-1499@assetmemo.bio
DTSTAMP:20261121T005812Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:soquelitinib: Phase 1 readout est. (NCT07828860)
DESCRIPTION:soquelitinib\, phase 1.\nStudy: Safety and Efficacy of Soquelit
 inib in Adults With Hidradenitis Suppurativa\nEstimated primary completion
 : December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/soqu
 elitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07828860
URL:https://assetmemo.bio/drug/soquelitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
